About Us
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory, and autoimmune diseases. Our focus is on the development of novel small molecule product candidates targeting Toll-like receptor 8 (TLR8).
VentiRx was founded in June 2006 and has raised $53.9 million. Our current investors are ARCH Venture Partners, Domain Associates, Frazier Healthcare Ventures, and MedImmune Ventures.